These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 31926465

  • 21. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
    Yang J, Gao J.
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):723-728. PubMed ID: 31215815
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G.
    Sleep Med; 2021 Mar; 79():40-47. PubMed ID: 33472129
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
    Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford DA.
    Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness.
    Fuller MC, Carlson S, Pysick H, Berry V, Tondryk A, Swartz H, Cornett EM, Kaye AM, Viswanath O, Urits I, Kaye AD.
    Psychopharmacol Bull; 2024 Mar 04; 54(1):65-86. PubMed ID: 38449471
    [Abstract] [Full Text] [Related]

  • 28. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial.
    Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A.
    Hum Psychopharmacol; 2023 Jan 04; 38(1):e2858. PubMed ID: 36420633
    [Abstract] [Full Text] [Related]

  • 29. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
    Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP.
    Clin Pharmacol Drug Dev; 2021 Apr 04; 10(4):404-413. PubMed ID: 32935460
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110.
    Scrima L, Emsellem HA, Becker PM, Ruoff C, Lankford A, Bream G, Khayrallah M, Lu Y, Black J.
    Sleep Med; 2017 Oct 04; 38():108-112. PubMed ID: 29031743
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
    Weil AJ, Masters ET, Barsdorf AI, Bass A, Pixton G, Wilson JG, Wolfram G.
    Health Qual Life Outcomes; 2017 Oct 17; 15(1):202. PubMed ID: 29041942
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.